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Introduction and Objectives

Results

Multi-parametric MRI (mp-MRI) rather than trans-rectal
ultrasound (TRUS)-guided prostate biopsy is becoming
more popular as the initial evaluation of a patient with
an elevated PSA or an abnormal prostate exam. If a
cancer suspicious region (CSR) is detected by mpMRI, the patient may undergo imaging-guided targeted
biopsy with or without a standard systematic biopsy.
Recently, there has been an increasing trend for
patients to undergo focal treatment for focal tumors to
avoid potential complications of surgery or radiation
therapy. The question is whether targeted biopsy
alone is sufficient to determine if the patient's tumor is
focal. The objectives of this study are to determine the
detection rate of prostate cancer (PCa) Gleason score
(GS) ≥ 7 in the opposite side of the prostate from the
CSRs and to determine if it is necessary to perform a
standard systematic prostate biopsy in addition to a
target biopsy.

On confirmatory MRI/US fusion-guided targeted biopsy,
56 of 68 patients had biopsy-proven PCa (82%).
Among them, 47 patients had PCa GS 7 (69%), 12 had
PCa GS 8 (18%) and 9 had GS 9 (13%). Nine of 68
patients (13%) had PCa GS ≥ 7 on the opposite side of
the prostate from the target lesions (GS 7, n=5 and GS
8, n=4) detected by the standard systematic biopsy.
The mean percentage of the positive core of PCa for
GS 7 was 40% and for GS 8 was 25%. Retrospective
review of these patients’ mp-MRI studies detected
corresponding CSRs with PI-RADS score 3 on the
opposite side from the target lesions in 3 of 9 patients.
There was no statistically significant difference in
patients' age, PSA, PSA density and prostate volume
between patients with or without PCa GS ≥ 7 on one
side (n=57) or both sides (n=9) of the prostate.
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Standard systematic biopsies should be added to US/MRI fusion
prostate biopsies in patients with no prior or ≥3 years prior TRUS
biopsy.
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Straight arrow: Lesion readily visualized on mpMRI. Targeted biopsy
confirmed PCa GS 7 (4+3), 60% in Left Base. Curved arrow: Systematic
TRUS biopsy picks up PCa GS 7 (4+3), 20% in Right Base without
evidence on mpMRI
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Sixty-eight consecutive men with elevated PSA, at
least one CSR detected on mp-MRI on a single side of
the prostate (right or left, not both) and no TRUSguided biopsy within the preceding 3 years underwent
MRI/US fusion-guided biopsy of CSRs and standard
systematic prostate biopsy (12 cores). Histopathology
results, including GS, location of cancer and
percentage of tumor involving positive cores, as well as
patients' clinical information, including age, PSA, PSA
density and prostate volume, were recorded. Two
experienced GU radiologists retrospectively reviewed
all mp-MRI studies blindly. The assessment included
but was not limited to location and PI-RADS scores of
CSRs. The findings from the imaging review were
correlated with the histopathology results. Statistical
significance of differences in clinical information
between patients with positive and negative biopsies
on the opposite side from the target lesion was
evaluated using Student’s T-test.

Standard Systemic Prostate Biopsy Results
Opposite to Target Lesions Seen on mpMRI
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Addition of standard systematic prostate biopsy to
targeted biopsy in patients with elevated PSA and no
prior systematic prostate biopsy within the preceding
3 years detected PCa GS ≥ 7 on the opposite side of
the prostate from the target lesions (with no
significant abnormalities on mp-MRI) in 13% of
patients. This result may influence treatment
choices, particularly for those patients considering
focal therapy for PCa.
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